logo

Eleven Biotherapeutics, Inc. (EBIO)



Trade EBIO now with
  Date
  Headline
11/20/2017 8:34:02 AM Eleven Biotherapeutics Q3 Net Loss $9.1 Mln Or $0.37/shr Vs. Net Income $19.5 Mln Or $0.91/shr Last Year
11/1/2017 9:35:16 AM Eleven Biotherapeutics Prices $8.0 Mln Public Offering
10/13/2017 4:35:05 PM Eleven Biotherapeutics Appoints Richard Fitzgerald As Interim CFO
8/14/2017 7:11:08 AM Eleven Biotherapeutics Q2 Loss Applicable To Stockholders $7.3 Mln Or $0.30/Shr Vs Loss $6.5 Mln Or $0.33/Shr Last Year
6/1/2017 8:14:35 AM Eleven Biotherapeutics Vicinium Phase 3 Registration Trial In Non-muscle Invasive Bladder Cancer Exceeds 50% Enrollment
5/4/2017 7:25:38 AM Eleven Biotherapeutics Q1 Revenue $0.4 Mln Vs $0.2 Mln Last Year
3/24/2017 7:02:16 AM Eleven Biotherapeutics Q4 Net Loss $3.5 Mln Or $0.15/Shr Vs Loss Of $10.3 Mln Or $0.53/Shr Last Year
11/14/2016 7:12:45 AM Eleven Biotherapeutics Q3 Revenue $28.7 Mln Vs. $0.1 Mln Last Year
9/21/2016 7:02:44 AM Eleven Biotherapeutics Agrees To, And Simultaneously Completes, The Acquisition Of Viventia
8/16/2016 7:32:13 AM Eleven Biotherapeutics Completes Exclusive Licensing Deal For IL-6 Antagonist Antibody Technology, Including EBI-031
8/12/2016 7:32:21 AM Eleven Biotherapeutics Q2 Loss Per Share $0.33 Vs Loss $0.36 Last Year